Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study.
Saved in:
| Title: | Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. |
|---|---|
| Authors: | Shen, Rong1 (AUTHOR), Cao, Wei‐Guo2 (AUTHOR), Wang, Li1,3 (AUTHOR), Sheng, Ling‐Shuang1 (AUTHOR), Zhang, Yi‐Lun1 (AUTHOR), Wu, Wen1 (AUTHOR), Xu, Peng‐Peng1 (AUTHOR), Cheng, Shu1 (AUTHOR), Liu, Meng‐Ke1 (AUTHOR), Dong, Yan1 (AUTHOR), Wang, Yue1 (AUTHOR), Weng, Xiang‐Qin1 (AUTHOR), Jiang, Xu‐Feng4 (AUTHOR), Song, Qi5 (AUTHOR), Yi, Hong‐Mei6 (AUTHOR), Li, Lei7 (AUTHOR), Chen, Sheng8 (AUTHOR), Yan, Zi‐Xun1 (AUTHOR) yanzixun125@163.com, Zhao, Wei‐Li1,3 (AUTHOR) zhao.weili@yahoo.com |
| Source: | Clinical & Translational Medicine. Apr2025, Vol. 15 Issue 4, p1-14. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
